KPV dosage: zero human trials, so where do the numbers come from?

Every milligram figure attached to KPV on a forum thread or a vendor’s dosing chart traces back to a mouse’s drinking water or a nanoparticle built to survive a mouse’s gut, never to a person. There is no dose-finding study, no pharmacokinetic trial, no case series, nothing. The numbers people quote are not a conservative extrapolation from thin human data. They are a guess dressed up as a protocol.

What the strongest available evidence shows, and its ceiling

KPV is the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-melanocyte-stimulating hormone. It lacks the sequence motif needed to bind any known melanocortin receptor, yet it keeps almost all of the parent hormone’s anti-inflammatory activity and none of its pigment-darkening effect^[1]. That dissociation, anti-inflammatory action without the receptor binding that normally drives it, is the only reason anyone studies KPV at all.

The most frequently cited efficacy data come from Kannengiesser and colleagues, who tested KPV in two well-described mouse models of inflammatory bowel disease: dextran sodium sulfate (DSS) colitis and CD45RB transfer colitis. KPV-treated mice recovered earlier, regained more weight, and showed less histologic inflammation and lower myeloperoxidase activity than untreated controls^[2]. A 2023 review of the melanocortin system in IBD describes KPV and related molecules as evidence “accumulated in mouse models of colitis,” framing them as potential future drug candidates rather than treatments already tested in people^[3].

That framing matters more than it sounds. Across every search pass run for this article, not one candidate source reported a human trial of KPV, by any dose or any route, which is what you would expect when the trial in question has never been run.

Interventional animal data, and why that still isn’t enough

The mouse studies are not observational. Researchers assigned KPV or a control, dosed it, and measured a defined outcome, which is the design that supports a causal claim. That claim just doesn’t extend past the species it was tested in.

A dose that resolves colitis in a 25-gram mouse colon cannot be rescaled into a human milligram figure by multiplying for body weight. Gut permeability, peptide metabolism and the ratio of surface area to volume all differ between a mouse and a person, and none of those differences cancel out cleanly in a weight-based conversion. The mouse experiments answer a mouse question. The human dosing question has not been asked in a lab, by anyone, yet.

Mechanism: PepT1, not a melanocortin receptor

Dalmasso and colleagues worked out why KPV does anything at all. In human intestinal cell lines (Caco2-BBE, HT29-Cl.19A) and human T cells (Jurkat) stimulated with inflammatory cytokines, nanomolar concentrations of KPV blocked NF-kB signaling after entering through PepT1, a di/tripeptide transporter, rather than by binding a receptor on the cell surface. The same effect held in DSS- and TNBS-induced colitis once the mechanism moved into mice^[4].

PepT1 is barely expressed in a healthy small intestine. Inflammatory bowel disease switches it on in the colon, which is precisely where the mouse experiments delivered KPV, through drinking water, straight to the tissue where the transporter was active^[4].

That single design choice explains the whole dosing problem. The researchers weren’t picking a dose to put KPV into general circulation; they were picking a dose to reach a transporter that only exists in meaningful quantity at the site of inflammation. A subcutaneous injection skips that transporter entirely and puts the peptide somewhere its only documented mechanism doesn’t operate.

The same substitution shows up elsewhere on this site. KPV has one working delivery route in mice, and it isn’t injection covers the route question directly: nobody has tested KPV by injection, in any species, for any reason. This article is about what happens once you ask the dosing question on top of that gap. The answer doesn’t improve.

Dosing as published in mouse studies, by route

Laroui and colleagues built the only KPV formulation with a published dose comparison. They loaded KPV into nanoparticles, wrapped those in an alginate-chitosan hydrogel so the payload survived the stomach and small intestine, and delivered the whole thing orally to mice with DSS colitis.

12,000-fold lower dose the nanoparticle formulation needed than free KPV in solution, for similar effect PMID 19909746

That number is real and it is the single most dose-specific fact published about KPV. It is also a statement about drug delivery efficiency inside a mouse colon, not a statement about what a human subcutaneous dose should be.

The one published KPV dose comparison

Laroui et al, 2010, mouse DSS colitis model.

No published study has tested a subcutaneous or intramuscular injection of KPV, in mice or in any other species. Across every search run for this piece, the injection route simply never appears as something anyone measured, in a paper, an abstract, or a footnote. People injecting KPV as part of a blend like KLOW are using a route with zero published dose-response data behind it, in any animal, let alone a person.

Safety and red flags, with no human data to anchor them

The mouse papers report colitis outcomes: weight regain, histology, inflammatory markers. They were not designed to catch systemic toxicity, and they don’t claim to. An absence of reported adverse events in a study built to measure colon healing just reflects what the experiment was looking for. It says nothing about whether KPV is safe anywhere else in the body.

There is no published data on how KPV interacts with prescription medications, including the biologics and immunosuppressants that people with inflammatory bowel disease are often already taking. Nobody has looked, because the human trial that would generate that data has never been run.

What the evidence does not establish: a safe human dose, a safe injection route, or any interaction profile. All three require a study that doesn’t exist yet.

Where this leaves someone deciding what to do

Anyone self-injecting KPV is combining two things that have never been tested together: a route (subcutaneous) that no study has examined in any species, and a dose extrapolated from a mouse colon experiment that was never designed to answer a human question. Stack those two guesses together and the result has nothing conservative about it.

A researcher-grade mouse colitis dose cannot be converted into a human dose by weight, by common sense, or by splitting a vial into smaller units. The conversion step that would make that number meaningful, a human pharmacokinetic study, hasn’t happened. Until it does, “KPV dosage” has a mouse’s answer and nothing resembling a researched human one.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.